SANOFI-AVENTIS (EPA:SAN) | WebDisclosure

Basculer en Français

9480	Companies
185563	Keywords
117965	Articles
99397	Press releases

Home
Companies
SANOFI-AVENTIS

BRIEF

published on 10/11/2024 at 08:35, 1 year 1 month ago

Sanofi considers selling majority stake in Opella

Participations Health Sanofi CD&R Opella
PRESS RELEASE

published on 10/11/2024 at 08:30, 1 year 1 month ago

Communiqué de presse : Sanofi en discussions pour céder une participation majoritaire dans Opella
Sanofi entame des discussions pour céder une participation majoritaire dans Opella à CD&R. Projet d'indépendance pour Opella aligné avec la stratégie de Sanofi. Opella est un acteur mondial en santé grand public

Cession Santé Sanofi CD&R Opella
PRESS RELEASE

published on 10/11/2024 at 08:30, 1 year 1 month ago

Press Release: Sanofi in discussions to sell a controlling stake in Opella
Sanofi is in discussions to sell a controlling stake in Opella, its consumer healthcare business, to CD&R. Opella aims for independence aligning with Sanofi’s focus on innovative medicines and vaccines

Negotiations Sale Sanofi Consumer Healthcare Opella
BRIEF

published on 10/09/2024 at 07:05, 1 year 1 month ago

Sanofi Highlights Beyfortus Effectiveness Against RSV in Infants

Sanofi RSV Beyfortus Infants IDWeek 2024
BRIEF

published on 10/09/2024 at 07:05, 1 year 1 month ago

Sanofi souligne l'efficacité de Beyfortus contre le VRS chez les nourrissons

Sanofi VRS Beyfortus Nourrissons Semaine Des ID 2024
PRESS RELEASE

published on 10/09/2024 at 07:00, 1 year 1 month ago

Press Release: New Beyfortus data featured at IDWeek reinforce real-world effectiveness against RSV disease and hospitalization in infants
Sanofi presents new Beyfortus data at IDWeek 2024, showcasing real-world effectiveness in protecting infants from RSV disease and hospitalization. Beyfortus doses shipped for 2024-2025 RSV season

Sanofi RSV Beyfortus Infants IDWeek
BRIEF

published on 09/27/2024 at 15:40, 1 year 2 months ago

Dupixent Approved in the US as First Biologic for COPD Patients

FDA Approval Clinical Studies COPD Dupixent Biologic Medicine
BRIEF

published on 09/27/2024 at 15:40, 1 year 2 months ago

Dupixent approuvé aux États-Unis comme premier médicament biologique pour les patients atteints de BPCO

MPoC Approbation De La FDA Études Cliniques Dupixent Médecine Biologique
PRESS RELEASE

published on 09/27/2024 at 15:35, 1 year 2 months ago

Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD
US FDA approves Dupixent as the first-ever biologic medicine for COPD, based on phase 3 studies showing significant reduction in exacerbations and improved lung function. Dupixent is now leading in new-to-brand prescriptions for FDA-approved indications

FDA Approval Dupixent COPD Treatment Biologic Medicine Phase 3 Studies
PRESS RELEASE

published on 09/27/2024 at 15:35, 1 year 2 months ago

Communiqué de presse : Dupixent est le premier médicament biologique approuvé aux États-Unis pour le traitement de la BPCO
La FDA approuve Dupixent comme premier médicament biologique pour la BPCO aux États-Unis, offrant un nouveau traitement aux patients inadéquatement contrôlés. Résultats positifs des études BOREAS et NOTUS

FDA Traitement Études BPCO Dupixent

Accesswire

Published on 12/06/2025 at 00:00, 20 minutes ago

Bird River Announces Closing of $0.10 Common Share Financing
Published on 12/05/2025 at 23:30, 50 minutes ago

55 North Mining Inc. Announces Completion of Third and Final Tranche of Private Placement for a Total of $4,202,000
Published on 12/05/2025 at 22:50, 1 hour 30 minutes ago

Banyan Gold Grants Incentive Stock Options
Published on 12/05/2025 at 21:45, 2 hours 35 minutes ago

When the Architecture Becomes Visible: The SMX Revaluation Explained
Published on 12/05/2025 at 21:30, 2 hours 50 minutes ago

The Identity Layer Beneath Everything: Why Markets Are Revaluing SMX All at Once

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 22:15, 2 hours 4 minutes ago

CPI PROPERTY GROUP - Changes in Shareholding and Board of Directors
Published on 12/05/2025 at 22:12, 2 hours 8 minutes ago

EQS-Adhoc: CPI PROPERTY GROUP - Change to Distribution Policy
Published on 12/05/2025 at 18:58, 5 hours 22 minutes ago

EQS-Adhoc: HORNBACH Holding AG & Co. KGaA: Reduced earnings in Q3 2025/26 – Guidance for adjusted EBIT at previous year’s level still valid
Published on 12/05/2025 at 18:26, 5 hours 53 minutes ago

POS-Transaction in Own Shares
Published on 12/05/2025 at 18:15, 6 hours 4 minutes ago

Completion of merger to form Helvetia Baloise Holding Ltd

Les Echos

Published on 12/05/2025 at 23:00, 1 hour 20 minutes ago

ALTAREIT : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 12/05/2025 at 23:00, 1 hour 20 minutes ago

ALTAREA : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 12/05/2025 at 23:00, 1 hour 20 minutes ago

ALTAREA : DÉCLARATION MENSUELLE DES OPÉRATIONS RÉALISÉES PAR LA SOCIÉTÉ SUR SES PROPRES TITRES NOVEMBRE 2025
Published on 12/05/2025 at 23:00, 1 hour 20 minutes ago

ALTAREIT : DÉCLARATION MENSUELLE DES OPÉRATIONS RÉALISÉES PAR LA SOCIÉTÉ SUR SES PROPRES TITRES NOVEMBRE 2025
Published on 12/05/2025 at 17:18, 7 hours 2 minutes ago

La vidéo de la réunion de présentation des résultats 2024-2025 du 5 décembre 2025 est disponible

View all LES ECHOS COMFI WIRE